PureTech Health plc

PRTC • Biotechnology

$17.38

▲ +0.36 (+2.12%)

Precio actual

ResultadosÚltimo reporte: 31 dic 2025

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$41.95M

Crecimiento

3.4%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Crecimiento positivo de ingresos · 53.5%Nivel de deuda manejable · 0.06Liquidez saludable · 6.59Rentabilidad débil

Datos financieros hasta: 31 dic 2025, 12:00 a.m. UTCÚltima actualización de earnings: 29 abr 2026, 12:00 a.m. UTCÚltima actualización del perfil: 27 ago 2026, 12:15 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$17.38

Change2.12%

Shares Out2.41M

Market Cap$41.95M

Enterprise Value$-228.28M

52W Range14.50 - 19.92

Beta0.76

P/E-0.75

P/S4.68

P/B0.13

P/FCF-0.19

EV/Sales-25.47

Price$17.38

Change2.12%

Shares Out2.41M

Market Cap$41.95M

Enterprise Value$-228.28M

52W Range14.50 - 19.92

Beta0.76

P/E-0.75

P/S4.68

P/B0.13

P/FCF-0.19

EV/Sales-25.47

EV/EBITDA3.96

EV/FCF1.05

Earnings Yield-133.46%

FCF Yield-519.33%

Dividend Yield0.00%

Gross Margin100.00%

Oper. Margin-21.15%

Profit Margin-23.55%

Debt/Eq0.06

Current Ratio6.59

Quick Ratio6.59

Revenue 5Y3.39%

Target$57.00

Target Upside227.96%

Target Median$57.00

Target Range44.00 - 70.00

Volume9.86K

Avg Volume9.19K

EPS Surprise-24.96

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

74/100

Por qué este puntaje▼

Crecimiento positivo de ingresos · 53.5%Nivel de deuda manejable · 0.06Liquidez saludable · 6.59Rentabilidad débil

Analyst view

Analyst sentiment and price target

PRTC

Analyst sentiment

Based on 2 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-27

Bajo

$44.00

Promedio

$57.00

Mediana

$57.00

Alto

$70.00

Resumen de la compañía

IPO: 11/16/2020

Industria: Biotechnology

P/B i: 0.13

Deuda / Patrimonio i: 0.06

Margen operativo: -2114.72%

Margen neto: -2355.42%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.06

Ratio corriente: 6.59

Ratio rápido: 6.59

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

PureTech Health plc

Transacción: 01/13/2022

OTRO

Cambio

+4,526,622

Precio

Not reported

Presentación

01/21/2022

Tipo

OTRO

PureTech Health plc

Transacción: 01/13/2022

OTRO

Cambio

+216,208

Precio

$0.02

Presentación

01/21/2022

Tipo

OTRO

PureTech Health plc

Transacción: 01/13/2022

OTRO

Cambio

+77,760

Precio

$4.05

Presentación

01/21/2022

Tipo

OTRO

Insider	Tipo	Cambio	Precio	Transacción	Presentación
PureTech Health plc	OTRO	+4,526,622	Not reported	01/13/2022	01/21/2022
PureTech Health plc	OTRO	+216,208	$0.02	01/13/2022	01/21/2022
PureTech Health plc	OTRO	+77,760	$4.05	01/13/2022	01/21/2022
PureTech Health plc	OTRO	0	Not reported	01/13/2022	01/21/2022

Sobre la compañía

PureTech Health plc

PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms. The Controlled Founded Entities segment is composed of the group’s subsidiaries that are currently consolidated operational subsidiaries that either have or have plans to hire independent management teams and currently have already raised, or are currently in the process of raising, third-party dilutive capital. The Non-Controlled Founded Entities segment includes companies wherein the group no longer holds majority voting control as a shareholder and no longer has the right to elect a majority of the members of the subsidiaries’ Board of Directors. The Parent Company and Other segment represents activities that are not directly attributable to the operating segments, such as the activities of the parent, corporate support functions and certain research and development support functions that are not directly attributable to a strategic business segment as well as the elimination of intercompany transactions. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.

Fuente - Link

Competidores

ADCT ALMS AUTL BNTC LCTX NGNE NMRA QSI RCKT SLDB

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

PureTech Health: Results of Annual General Meeting

BOSTON--(BUSINESS WIRE)--PureTech Health: Results of Annual General Meeting.

Business Wire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-04-29	-1.94	-26.9	-24.96
2025-08-28	-2.04	-1.85882	0.18118
2025-04-30	-2.83	0.3533	3.1833
2024-08-28	-3.03	-0.15491	2.87509
2024-04-25	-3.25	-0.14714	3.10286
2023-04-28	0.34	-0.08194	-0.42194
2022-08-25	-2.745	-0.0985	2.6465
2022-04-21	-2.45	0.05215	2.50215
2021-08-24	-2.31	-0.26361	2.04639
2021-04-15	-2.005	-0.4055	1.5995